Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy

Lymphadenopathy after coronavirus disease 2019 (COVID-19) vaccination is a common side effect that usually resolves within several days to weeks, and only observation is recommended. However, for prolonged lymphadenopathy, other possibilities, including malignancy or other lymphoproliferative diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Han Gyu, Kim, Dong Gyu, Choi, Joon Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230702/
https://www.ncbi.nlm.nih.gov/pubmed/35746572
http://dx.doi.org/10.3390/vaccines10060964
_version_ 1784735131595964416
author Cha, Han Gyu
Kim, Dong Gyu
Choi, Joon Ho
author_facet Cha, Han Gyu
Kim, Dong Gyu
Choi, Joon Ho
author_sort Cha, Han Gyu
collection PubMed
description Lymphadenopathy after coronavirus disease 2019 (COVID-19) vaccination is a common side effect that usually resolves within several days to weeks, and only observation is recommended. However, for prolonged lymphadenopathy, other possibilities, including malignancy or other lymphoproliferative diseases, may be considered. Herein, we report the case of a 66-year-old woman who experienced prolonged ipsilateral supraclavicular lymph node enlargement after the second dose of the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccine, which was eventually diagnosed as extrapulmonary tuberculosis.
format Online
Article
Text
id pubmed-9230702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92307022022-06-25 Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy Cha, Han Gyu Kim, Dong Gyu Choi, Joon Ho Vaccines (Basel) Case Report Lymphadenopathy after coronavirus disease 2019 (COVID-19) vaccination is a common side effect that usually resolves within several days to weeks, and only observation is recommended. However, for prolonged lymphadenopathy, other possibilities, including malignancy or other lymphoproliferative diseases, may be considered. Herein, we report the case of a 66-year-old woman who experienced prolonged ipsilateral supraclavicular lymph node enlargement after the second dose of the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccine, which was eventually diagnosed as extrapulmonary tuberculosis. MDPI 2022-06-16 /pmc/articles/PMC9230702/ /pubmed/35746572 http://dx.doi.org/10.3390/vaccines10060964 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Cha, Han Gyu
Kim, Dong Gyu
Choi, Joon Ho
Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy
title Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy
title_full Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy
title_fullStr Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy
title_full_unstemmed Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy
title_short Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy
title_sort manifestation of subclinical extrapulmonary tuberculosis after covid-19 vaccination as supraclavicular lymphadenopathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230702/
https://www.ncbi.nlm.nih.gov/pubmed/35746572
http://dx.doi.org/10.3390/vaccines10060964
work_keys_str_mv AT chahangyu manifestationofsubclinicalextrapulmonarytuberculosisaftercovid19vaccinationassupraclavicularlymphadenopathy
AT kimdonggyu manifestationofsubclinicalextrapulmonarytuberculosisaftercovid19vaccinationassupraclavicularlymphadenopathy
AT choijoonho manifestationofsubclinicalextrapulmonarytuberculosisaftercovid19vaccinationassupraclavicularlymphadenopathy

Ejemplares similares